BCAX News
Archived Headlines
- Oncology biotech Bicara Therapeutics sets terms for $200 million IPO 09/06/24
- Renaissance Capital's August IPO Market Update 09/03/24
- Fall 2024 US IPO Preview: Steady Flow of Deals to Close Out the Year 08/30/24
- US IPO Weekly Recap: WeRide delays its IPO as pipeline gets a boost 08/23/24
- Oncology biotech Bicara Therapeutics files for a $200 million IPO 08/22/24
Updated: Renaissance Capital's 3Q 2024 US IPO Market Review
US IPO Market’s Slow Rebound Continues as Focus Shifts to 2025 While the IPO market’s annual fall pickup was more muted than anticipated, the third quarter still saw a fair amount of...read more
Oncology biotech Bicara Therapeutics prices upsized IPO at $18, the high end of the range
Bicara Therapeutics, a Phase 1 biotech developing a bifunctional antibody to target solid tumors, raised $315 million by offering 17.5 million shares at $18, the high end of the $16 to $18 range. The company originally filed to raise $200 million, before it...read more
Oncology biotech Bicara Therapeutics increases shares offered 25% ahead of $250 million IPO
Bicara Therapeutics, a Phase 1 biotech developing a bifunctional antibody to target solid tumors, raised the proposed deal size for its upcoming IPO on Wednesday. The Boston, MA-based company now plans to raise $250 million by offering 14.7 million shares at a...read more
US IPO Week Ahead: A trio of biotechs kick off fall IPO market
Updated Monday 9/9/24 Three biotechs are scheduled to complete IPOs this week. Bicara Therapeutics (BCAX) plans to raise $200 million at an $865 million market cap. Its lead candidate, ficerafusp alfa, is a bifunctional...read more